Ian Kirby

This inventor holds 28 USPTO granted patents and 33 published patent applications, plus 3 CIPO patents and 6 EPO patents, primarily in Antibody Therapeutics. Top assignees: Kymab Limited, Glaxo Group Limited. Active years: 2014-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ian Kirby. Retrieved from https://idiyas.com/inventor/ian-kirby

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 28 (Patent Applications = 33)

% Patents Active = 85.7

CIPO Patents = 3 (Patent Applications = 4)

EPO Patents = 6 (Patent Applications = 15)

Average Co-Inventor Count = 5.5

ph-index = 9

Forward Citations = 276(Granted Patents)

Location History:

Stevenage, GB (2014 - 2020)
Cambridge, GB (2015 - 2024)

Company Filing History:

Years Active: 2014-2026

Loading Chart...

Areas of Expertise:

Anti-OX40L Antibodies

Anti-PD-L1 Antibodies

Immunocytokines

Graft Versus Host Disease

Animal Models

Cytokines

Antigen Binding Proteins

Therapeutic Molecules

Nucleic Acids

Synergistic Combinations

Methods of Treatment

CD127 Binding Proteins

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. RE50880 - Anti-Human OX40L Antibodies and Methods of Treatment (2026-05-05),

2. 12209128 - Anti-PD-L1 antibodies (2025-01-28),

3. 11965026 - Anti-PD-L1 and IL-2 cytokines (2024-04-23),

4. 11858996 - Anti-ICOS antibodies (2024-01-02),

5. 11812731 - Animal models and therapeutic molecules (2023-11-14),

6. 11773175 - Antibodies, uses and methods (2023-10-03),

7. 11753479 - Nucleic acids encoding anti-OX40L antibodies (2023-09-12),

8. 11440960 - TIGIT antibodies, encoding nucleic acids and methods of using said antibodies in vivo (2022-09-13),

9. 11396550 - Methods of treating comprising administering anti-OX40L antibodies (2022-07-26),

10. 10808029 - Antigen binding proteins to oncostatin M (OSM) (2020-10-20),

11. 10669342 - Anti-OX40L antibodies and methods of treating graft versus host disease (2020-06-02),

12. 10654935 - Methods of treating SLE with anti-OX40L antibodies (2020-05-19),

13. 10604576 - Antibodies and immunocytokines (2020-03-31),

14. 10259880 - Anti-LIGHT antibodies (2019-04-16),

15. 9957323 - Anti-ICOS antibodies (2018-05-01),

Title: Ian Kirby: Innovator in Anti-PD-L1 Antibodies

Introduction: Ian Kirby, based in Cambridge, GB, is a distinguished inventor known for his extensive contributions to the field of biomedicine, particularly through his innovative work on anti-PD-L1 antibodies. With a remarkable portfolio of 22 patents, his research is pivotal in the development of new therapeutic approaches for various diseases.

Latest Patents: Ian Kirby's latest inventions include groundbreaking patents focused on anti-PD-L1 antibodies and their applications. His patents describe bispecific antibodies that include one domain with specificity to PD-L1, as well as immunocytokines that comprise an anti-PD-L1 antibody fused to a cytokine, such as IL-2. These inventions not only highlight the antibodies and bispecific antibodies but also detail methods of treatment, uses, and pharmaceutical compositions related to these innovative solutions.

Career Highlights: Ian Kirby has made significant strides in the biomedical field through his role at Kymab Limited, where he continues to push the boundaries of immunotherapeutic research. His expertise in the development of antibodies has contributed to numerous advancements in treating immune-related conditions.

Collaborations: Throughout his career, Ian has collaborated with notable colleagues, including Miha Kosmac and Jamie Iain Campbell. These partnerships emphasize his commitment to fostering innovation through teamwork and shared expertise in the scientific community.

Conclusion: Ian Kirby exemplifies the role of an inventive scientist dedicated to advancing medical research. His innovative patents regarding anti-PD-L1 antibodies position him as a key figure in the ongoing pursuit of effective treatment options for patients worldwide. Through his work at Kymab Limited and his collaborations with other experts, Ian Kirby's contributions are setting the stage for future breakthroughs in immunotherapy.

Profile summary based on public USPTO records.